Safety tool

How to verify a tirzepatide compounding pharmacy

A telehealth website is not a pharmacy. The product you inject comes from a specific licensed pharmacy or outsourcing facility, and you can verify it in about ten minutes.

AT
Affordable Tirzepatide Guide editorial team
Published August 26, 2026
Direct answer as of August 26, 2026

To verify the pharmacy behind your compounded tirzepatide: get its name and state in writing from the provider, confirm its license on that state’s board of pharmacy lookup (NABP lists every board), check whether it is a 503A pharmacy or a 503B outsourcing facility, and match the name on your vial label to the name you were given. Ask for lot-level testing documentation.

The five-step check

  1. Get the pharmacy in writing before you pay. Name, city and state, and whether it is a 503A pharmacy or a 503B outsourcing facility. Providers that route to different pharmacies by state should name yours.
  2. Look up the license. Every state board of pharmacy publishes a license search; the NABP directory of state boards of pharmacy links to all of them. Check that the license is active, that it covers non-resident dispensing into your state if the pharmacy is elsewhere, and whether there is disciplinary history.
  3. For 503B facilities, check FDA’s registration list (FDA list of registered 503B outsourcing facilities), which also shows inspection outcomes and whether the facility has reported adverse events.
  4. Match the vial to the promise. When the package arrives, the label should show your name, the drug and concentration (mg/mL), a beyond-use date, the pharmacy’s name and address, and directions. A vial with no pharmacy name, or a different pharmacy than promised, is a reason to stop and call.
  5. Ask about testing. Sterile injectables should be tested for potency, sterility and endotoxin per lot (503A: USP <797>; 503B: CGMP). Ask whether a certificate of analysis for your lot is available on request.

Reading the label

Label elementWhat to look forWhy
Patient nameYour name503A preparations are patient-specific
Drug and strength“Tirzepatide” and a concentration such as 10 mg/mLYour weekly dose in mg divided by the concentration gives the volume to draw. Concentrations differ between pharmacies.
Beyond-use date (BUD)A specific date, sometimes with a second date after first punctureThe BUD is the compounder’s stated limit, unlike a manufacturer’s expiration date. Do not use past it.
Pharmacy name, address, phoneMatches what the provider told youThis is who you call about the product
Storage instructionsUsually refrigerate; do not freezeStorage and shipping guide
AdditivesAnything besides tirzepatide and standard excipientsVitamins or other actives added to tirzepatide have no trial evidence; FDA has raised concerns

Signs the FDA lists for a legitimate online pharmacy

FDA’s BeSafeRx program describes the basics: it requires a valid prescription, it has a physical U.S. address and phone number, a licensed pharmacist is available to answer questions, and it is licensed by the state board of pharmacy (FDA BeSafeRx: considering an online pharmacy). Telehealth providers are not pharmacies; the dispensing pharmacy behind them must meet these tests.

What to do if the names do not match

Do not use the product until the provider explains the difference in writing. Providers do change pharmacies; a legitimate provider will name the new pharmacy, confirm its license for your state and, if you ask, explain why it changed. If you cannot get that answer, the state board that licenses the pharmacy on the label can confirm whether it is authorized to dispense to you.

Frequently asked questions

How can I verify which pharmacy made my compounded tirzepatide?

Read the pharmacy name and address on the vial label, then look that pharmacy up on its state board of pharmacy license search (the NABP directory links to every board). Compare it with the pharmacy the provider named in writing. If they differ, ask before using the product.

What does beyond-use date mean on a compounded tirzepatide vial?

The beyond-use date is the date after which the compounding pharmacy no longer stands behind the preparation’s sterility and potency. It is set by the compounder under USP <797> (503A) or stability testing (503B). It is usually much shorter than a manufacturer’s expiration date and may shorten further once the vial is first punctured.

Should a provider name its pharmacy?

Yes. A provider that will not tell you which licensed pharmacy fills your prescription is asking you to trust an unverifiable product. Naming the pharmacy is one of the criteria in our provider comparison.

Can I ask for a certificate of analysis?

You can ask. Some pharmacies and outsourcing facilities provide lot-level testing summaries on request; others will only confirm that testing is performed. A refusal to say anything about testing is a red flag.

Primary sources

  1. NABP directory of state boards of pharmacy
  2. FDA list of registered 503B outsourcing facilities
  3. FDA BeSafeRx: considering an online pharmacy
  4. USP General Chapter <797> (sterile compounding)
  5. FDA: concerns with unapproved GLP-1 drugs used for weight loss

Change log

Substantive changes to this page are logged so readers and AI systems can judge how current it is.

DateChange
August 26, 2026Page created. Provider-to-pharmacy evidence table to follow as pharmacy relationships are verified with each provider.